Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB + [14] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Aug 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11550 | Bimekizumab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hidradenitis Suppurativa | European Union | 30 Apr 2024 | |
Hidradenitis Suppurativa | Iceland | 30 Apr 2024 | |
Hidradenitis Suppurativa | Liechtenstein | 30 Apr 2024 | |
Hidradenitis Suppurativa | Norway | 30 Apr 2024 | |
Ankylosing Spondylitis | European Union | 15 Jun 2023 | |
Ankylosing Spondylitis | Iceland | 15 Jun 2023 | |
Ankylosing Spondylitis | Liechtenstein | 15 Jun 2023 | |
Ankylosing Spondylitis | Norway | 15 Jun 2023 | |
Axial Spondyloarthritis | European Union | 15 Jun 2023 | |
Axial Spondyloarthritis | Iceland | 15 Jun 2023 | |
Axial Spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Axial Spondyloarthritis | Norway | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | European Union | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Iceland | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Norway | 15 Jun 2023 | |
Erythrodermic psoriasis | Japan | 20 Jan 2022 | |
Psoriasis vulgaris | Japan | 20 Jan 2022 | |
Pustular psoriasis | Japan | 20 Jan 2022 | |
Arthritis, Psoriatic | European Union | 20 Aug 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pustulosis of Palms and Soles | Phase 3 | United States | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | China | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Canada | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Czechia | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Denmark | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | France | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Germany | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Hungary | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Italy | 09 Oct 2025 | |
Pustulosis of Palms and Soles | Phase 3 | Poland | 09 Oct 2025 |
Phase 3 | 291 | (non-radiographic [nr-]axSpA + Week 52) | tqreytmjnt(wbjahirqht) = rtxzahmywo lutclfengi (uwumlfqahq ) | Positive | 11 Jun 2025 | ||
tqreytmjnt(wbjahirqht) = ootexvhqds lutclfengi (uwumlfqahq ) | |||||||
Phase 3 | 299 | vzwevjcnnn(voowrdqgpf) = vbfbscvrpc btniotkzof (acnwbaycnz ) View more | Positive | 11 Jun 2025 | |||
Phase 3 | 584 | ejvjpjdrfs(ojecbdzxzl) = ybsrorrhkr synedijtmh (cftxaijufu ) | Positive | 11 Jun 2025 | |||
Phase 3 | Arthritis, Psoriatic bDMARD-naïve | inadequate response/intolerance to tumor necrosis factor inhibitors | - | Bimekizumab 160 mg every 4 weeks | oiegzqnnmp(tmsezpxfxg) = cvxybxsyla pzweibksbk (vjmslhpjrw ) View more | Positive | 01 May 2025 | |
Phase 1 | - | 121 | (Bimekizumab-AI-2mL (Test)) | rhzobkoawl(ikfvbwwxsq) = fpixzfetiw klphcwhlxi (rybkcoyyey, etmnjkkdnj - jvtqsinllk) View more | - | 10 Apr 2025 | |
(Bimekizumab-AI-2x1mL (Reference)) | rhzobkoawl(ikfvbwwxsq) = gbhmldxyxv klphcwhlxi (rybkcoyyey, nufonbcohp - vchzovjwsv) View more | ||||||
Phase 1 | - | 71 | (Bimekizumab-SS-2mL (Test 1)) | tqluwahxvc(mkucrlhbmw) = tyoklueyeq ngdrlxyyhu (iibeumrjqr, 34.2) View more | - | 10 Apr 2025 | |
(Bimekizumab-SS-2x1mL (Reference 1)) | tqluwahxvc(mkucrlhbmw) = msszmvmodo ngdrlxyyhu (iibeumrjqr, 31.3) View more | ||||||
Phase 2/3 | 2,255 | (axial spondyloarthritis) | wqudchxlyt(hdbdgxrgpl) = ubumgmjuix epbjuzlyzf (alizwkfkcc ) View more | Positive | 01 Apr 2025 | ||
(psoriatic arthritis) | wqudchxlyt(hdbdgxrgpl) = njbgluizvq epbjuzlyzf (alizwkfkcc ) View more | ||||||
Phase 3 | - | Bimekizumab 320 mg via 2 mL Safety Syringe | illhkbtioa(cbgemsgdjq) = all adverse device effects reported were mild and did not lead to discontinuation ngqapcpteq (qvlppehijb ) View more | - | 29 Mar 2025 | ||
Phase 3 | 505 | placebo (Placebo) | lsuvcwfxzm = wzjebrgwip sdvwrplhkw (zoqieklcum, bvscvoxmlq - ygwmtwvtwp) View more | - | 09 Jan 2025 | ||
(BKZ Dosing Regimen 1) | lsuvcwfxzm = pgxlopumav sdvwrplhkw (zoqieklcum, dvirxlhxpt - jttlzgtrdj) View more | ||||||
Phase 2 | - | Bimekizumab 160 mg every 4 weeks | ihpzntfpeq(bcooawbhhe) = mjlhjpeuwa riscvazcco (abihudvzzv ) View more | Positive | 01 Jan 2025 |